Ethical Pharmaceuticals Market is Gaining Traction through Increased Focus on Patient-Centric Healthcare

Ethical pharmaceuticals, also known as prescription drugs, are medicinal products that are intended for use only under professional supervision. These products contain ingredients that have the potential for harmful effects, and as such require careful medical management. Ethical pharmaceuticals play a crucial role in disease treatment and management by offering medical advantages like targeted disease treatment, convenient administration, and improved patient compliance. The growing prevalence of chronic diseases and increasing healthcare investments are major factors driving the demand for ethical pharmaceuticals globally.

The Global Ethical Pharmaceuticals Market is estimated to be valued at US$ 4.76 billion in 2024 and is expected to exhibit a CAGR of 10% over the forecast period from 2024 to 2031.

Key Takeaways

Key players: The Global Ethical Pharmaceuticals Market is fragmented with the presence of several global and regional players. Key players operating in the ethical pharmaceuticals market are Amgen Inc, AbbVie Inc, Johnson & Johnson, Eli Lilly and Company, Merck & Co., Inc, GlaxoSmithKline plc, Sanofi, Novartis AG, Abbott Laboratories, Otsuka Holdings, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Pfizer Inc, Takeda Pharmaceutical Company. The major global players are focusing on developing novel drugs through aggressive R&D initiatives to gain a competitive edge. For instance, in 2022, Amgen Inc received FDA approval for its LUMAKRAS drug to treat lung cancer. Such new product launches are helping key players expand their portfolio and strengthen market presence.


Growing demand: Rising awareness about diseases and available treatment options has been fueling the demand for ethical pharmaceuticals. Increased healthcare expenditures in developing nations are also contributing to market growth. Further, the growing geriatric population prone to chronic diseases acts as a high-impact rendering driver.

Global expansion: Leading companies are focusing on expanding their global footprint through strategies like acquisitions, collaborations, and geographic expansions. For example, in 2021, Novartis AG acquired US-based therapeutic company The Medicines Company for USD 9.7 billion to enhance its cardiovascular portfolio.

Market key trends

Increased focus on patient-centric healthcare: Pharmaceutical firms are shifting their strategy from volume-based to value-based healthcare with more focus on patient needs. This involves developing drugs with better safety profiles, convenient dosage forms and customized treatment options. For instance, Amgen launched migraine drug AIMOVA in 2022 which offers ease of self-administration.

Growth in specialty drugs: There is high demand for specialty drugs used to treat complex conditions like cancer and autoimmune diseases. Biosimilars and targeted therapies have shown promising results with fewer side effects. Areas like oncology and immunology will drive most revenues in specialty drug segments going forward.

Porter's Analysis

Threat of new entrants: Ethical pharmaceutical industry requires huge capital investments for R&D and clinical trials. Regulations also pose barriers.

Bargaining power of buyers: Large buyers like governments and hospitals can negotiate prices but individual consumers have less influence.

Bargaining power of suppliers: Key raw material suppliers possess some bargaining power. However, industry players try to vertically integrate or find alternative suppliers to reduce dependence.

Threat of new substitutes: New drug delivery technologies or alternative treatment options can disrupt existing products but require extensive testing before commercial use.

Competitive rivalry: The global pharmaceutical market is highly competitive with major players continuously investing in R&D to develop innovative drugs and diversify their product portfolios.

Geographical Regions

North America accounts for the largest share of the global ethical pharmaceuticals market currently, due to high healthcare expenditure and presence of leading industry players in the US and Canada.

Asia Pacific is poised to be the fastest growing regional market during the forecast period, driven by rising income levels, growing medical tourism industry and increasing healthcare investments in major economies like China and India.

Comments

Post a Comment

Popular posts from this blog

Vegan Yogurt Market is Poised for Growth Driven by Rising Health Consciousness

Image
Vegan yogurt is a dairy-free alternative to conventional yogurt made from plant-based milk such as soy, almond, oat, coconut or rice. It provides similar texture and taste to dairy yogurt but without any animal products.Vegan yogurt offers several health advantages over dairy yogurt as it is devoid of lactose, cholesterol and saturated fats. The growing number of people adopting vegan and flexitarian diets has driven the demand for plant-based dairy alternatives like vegan yogurt. The global vegan yogurt market is estimated to be valued at US$ 4.15 Mn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024 to 2031. Key Takeaways Key players- Met Fods, Cocos Organic, Hain Celestial, EasiYo Product Limited, Danone, General Mills Inc., Stonyfield Far, Inc., Daiya Foods Inc.m Good Karma foods, Inc.m Hudson River Foodsm NANCY'S, Kite Hill, COYO Pty lTd., Nush Foods, Chobani, LLC, Barambah Oraganics Pty Ltd., Blue Diamond Growers, Dean Foodsm General Mills Inc...
Read more

Hypoglycemic Drugs Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Diabetes in the Geriatric Population

Image
Hypoglycemic drugs or anti-diabetic drugs are medications used to treat diabetes mellitus by lowering blood glucose levels. Some key hypoglycemic drugs include insulin, sulfonylureas, metformin, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists. These drugs help control blood sugar levels in diabetics and prevent or delay diabetes-related health complications. The global hypoglycemic drugs market is estimated to be valued at US$ 720.72 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The growth of the global hypoglycemic drugs market is majorly driven by the increasing prevalence of diabetes in the geriatric population globally. As per estimates, around 1 in every 11 people aged 65 years and above have diabetes. Further, the number of people with diabetes in this age group is anticipated to grow from 25.9 million in 2017 to...
Read more

Clinical Trials Rising with Digital Technologies Adoption

Image
 Clinical trials support services play a vital role in assisting sponsors and life science companies to conduct clinical trials in a precise and well-organized manner.These services assist pharmaceutical companies in patient recruitment, data management, site management, and overall clinical trial management. With rising complexities in clinical trials owing to integration of technologies like telehealth and remote patient monitoring, the demand for these support services is growing substantially. The global Clinical Trials Support Services Market is estimated to be valued at US$ 22.38 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: The growing adoption of digital technologies across clinical trials is a key trend accelerating the growth of the clinical trials support services market. Digital tools like electronic data capture, clinical trial manag...
Read more